Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.
CAR T-Cell Agents Offer Efficacy in Lymphoma, But Additional Approaches Are Needed to Overcome Resistance
Revisit the OncLive On Air Episodes From February 2024
Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer